Back to 1999 1st Quarter Table of Contents
First published in Journal of Orthomolecu-lar Medicine, Vol. 5, No.1, 1990
The adrenochrome hypothesis of schizo-phrenia (Hoffer, Osmond and Smythies, 1954), was stimulated by the work of Osmond and Smythies (1952) which focused on methyl-ated derivatives of adrenalin as possible en-dogenous schizophrenogens. They showed that the experience which followed the inges-tion of mescaline was in many ways similar to the experience induced in normal people by schizophrenia. This drew attention to de-rivatives of adrenalin (and of all the sym-pathomimetic amines and their precursors) as etiological factors. However, in 1952 very few of these compounds had been studied. With our resources we were forced to limit our studies to one derivative, adrenochrome, an oxidized, coloured derivative of adrenalin. So little was known about its chemistry it was not surprising chemists had concluded, in-correctly, it was inherently unstable and dif-ficult to study. We allocated much of our chemical researches to this interesting sub-stance. As a result, under the direction of Dr. R. Heacock (1959, 1965), an enormous body of data was gathered and published detailing the chemistry of adrenochrome, its synthesis, metabolism, conversion to other products and its reactions with substances like ascorbic acid.
Adrenochrome is a member of a class of chemicals known as aminochromes, each one derived by the oxidation of its precursor amine. Thus, 1-dihydroxy pheny-lalanine (L-dopa) is oxidized to dopachrome; tyrosine to a series of coloured indoles; no-radrenalin to noradrenochrome and adren-alin to adrenochrome. The chemistry of these oxidation reactions is very complex for these compounds are very reactive. They are formed via free radicals and rapidly break down to several classes of trihydroxy and dihydroxy N methyl indoles. Adrenolutin is the best known example of trihydroxy N methyl indole, and leukoadrenochrome is the best known of the dihydroxy N methyl indoles. Both are derived from adreno-chrome. Adrenolutin is coloured yellow and is toxic, as is adrenochrome. It is psychoto-mimetic. Leukoadrenochrome is colourless and non-toxic. On the contrary, even in small doses given sublingually, it has anti-tension and anti-anxiety properties. Adrenolutin is more stable than adreno-chrome.
The aminochromes polymerize readily, forming a complex system of melanins. Recently the melanins have been consid-ered among the most important organiz-ing systems in the body.
We also published a large series of clini-cal studies showing adrenochrome and andrenolutin were hallucinogens. These studies are described in our book, The Hal-lucinogens (Hoffer, Osmond, 1967). That re-view is still pertinent for the whole area of adrenochrome investigation went into hi-bernation for a number of reasons, espe-cially in psychiatry. In 1981 Hoffer wrote, “Interest in the amino-chromes is return-ing because some of the properties of the centrally active amines can not be under-stood unless their degradation into these oxidized derivatives is considered.”
The dopamine hypothesis of schizo-phrenia is widely known and accepted, even though it is a simple “too much or too lit-tle” idea, i.e. in schizophrenics there may be too much dopamine, or too little. Major support was provided by the finding that tranquilizers block dopamine receptors. Ascorbic acid also blocks dopamine receptors but so far this finding has been ignored–it is embarrassing to have a vita-min have the same effect as a tranquilizer.
Hoffer (1981) concluded, “The adreno-chrome hypothesis accounts for the syn-drome of schizophrenia more accurately than do any of the competing hypotheses. The two main hypotheses are superfluous since they are accommodated by the adreno-chrome or, more accurately, the amino-chrome hypothesis.”
Recently Cadet and Lohr (1987) came to the same conclusion. They summarized their report as follows: “The dopamine hy-pothesis has been criticized because it fails to explain many clinical facts and bio-chemical findings in schizophrenic pa-tients. After a review of the possible neu-rotoxic effects of free radicals formed dur-ing states of high dopamine turnover, we postulate that the neuronal damage caused during these episodes might form the substrate of a comprehensive hypothesis that could potentially explain the protean findings in the group of schizophrenias and the progression of the syndrome, in some patients, to the so-called schizophrenic defect state.”
We find this hypothesis very interest-ing for it is exactly what we have been pro-posing since we first publicly discussed our adrenochrome hypothesis in 1952 before the Dementia Praecox Committee of the Scot-tish Rites Masons in New York.
Hoffer (1981) wrote, “Unfortunately the many leads developed by the adreno-chrome hypothesis have been neglected by research institutions for a number of rea-sons. The critical and hostile attitude of the professional associations and granting agencies discouraged scientists from enter-ing this difficult but challenging field. For-tunately the climate of opinion is chang-ing. I expect that for the next decade the aminochrome hypothesis will receive more careful attention.”
We think it is appropriate to review the aminochrome hypothesis of schizophrenia, for in our opinion it is a powerful hypoth-esis. Hypotheses are needed to direct re-search. They are not forever, for with new information they must inevitably change. But the aminochrome (adrenochrome) hy-pothesis has not yet run its course. It should lead to even better treatment for all diseases in which oxidation (by enzymes or by auto-oxidation) plays a role
The Original Adrenochrome Hypothesis
This was developed between 1952 and 1954 when little was known about the chemistry and physiology of adrenochrome. All we did know was that it was readily formed by oxidation of adrenalin to a red compound in solution. It was “known” that it was inherently unstable and therefore could not form stable crystals. But very lit-tle was known about enzymes which could oxidize adrenalin, about pathways, and whether it was made in the body. Nothing was known about its effect on the brain. it was known to be an enzyme inhibitor and had antimitotic properties. But we sus-pected it might be an hallucinogen because pink or deteriorated adrenalin was, and it resembled the few known hallucinogens like d-lysergic acid diethylamide (LSD), and ibogaine. Mescaline is not an indole but resembles adrenalin and could be indolized in the body. It is now known that methyl-ated derivatives of sympathomimetic amines do form aminochrome derivatives. Amino-chrome is a term applied to all chrome indoles; derived from catecholamines (sym-pathomimetic amines).
Our hypothesis was prepared as a se-ries of simple equations:
i.e. schizophrenia arose in an individual when too much adrenochrome was formed, that adrenochrome then interfered with brain function as would LSD, and that cre-ated the essential stage for the formation of schizophrenia.
To test this hypothesis we needed data in a minimum of three areas: (1) was adrenochrome made in the body, where, how much, by which enzymes? (2) was adrenochrome an hallucinogen? (3) would reversing or preventing the formation of adrenochrome be therapeutic for schizo-phrenia. If these were all found to be true, it would provide strong support for the adrenochrome hypothesis. If any one were negative it would be very difficult to sus-tain. We believe our adrenochrome hypoth-esis is a good one and will now show why we think so.
Is Adrenochrome Made in the Body?
As soon as scientists discovered adrenalin turned pink in solution it ap-peared likely that what happened in vitro could also occur in the body. Adrenalin is a member of a class of catecholamines which polymerize very readily. The melanins are these polymerized, oxidized and indolized catechol-amines. All the conditions re-quired for the oxidation of adrenalin to adrenochrome in vivo are present. These are: (1) the substrate - noradrenalin, adrenalin; (2) the enzymes and metallic oxidizers which convert adrenalin to adrenochrome, or accelerate its auto-oxi-dation. Auto-oxidation does not require an enzyme. The oxidation of adrenalin to adrenochrome in water is an example. It requires oxygen and is accelerated by traces of metal such as copper ions. We have dis-cussed the theoretical argument for the formation of adrenochrome in several pre-vious reports (Hoffer, 1981, 1983, 1985; Hoffer and Osmond, 1967).
Ideally, final proof would have been gained when adrenochrome crystals ex-tracted from the body are in one’s hand. But because adrenochrome in solution is so reactive it is highly unlikely it can be ex-tracted. It will have to be stabilized first by combining it with another molecule. Adrenochrome semicarbazide is a stable derivative. Perhaps this could be made in blood or other fluids and then extracted.
However, any stable derivative will do. Nature has already made a number of sta-ble derivatives of the catecholamines. Thus, tyrosine forms the melanins in skin and other tissues. Albinos are without melanin pigment because their bodies do not have the enzyme needed to oxidize the tyrosine to melanin. Albinos do have a reddish pig-ment in the pigmented areas of their brains. They can form pigmented indoles, most likely from noradrenalin and adrenalin. Tyrosine melanin is more in the brown/ black/red area compared to neuromelanin which is usually red. Adrenochrome and noradrenochrome are red. (Hegedus and Altschule, 1968, 1970, 1970a; Hegedus, Kuttab, Altschule and Nayak, 1981).
Adrenolutin is another derivative of adrenochrome and more stable in blood. Hoffer and Kenyon (1957) showed that the compound made in blood from adrenaline (Leach and Heath, 1956), was adrenolutin. Leach and Heath found that the rate of con-version was greater in schizophrenic blood compared to normal blood. In our studies, adrenaline added to serum was gone within one hour and replaced by adrenolutin. There it is more stable due to the presence of re-ducing substances such as ascorbic acid, glutathione, and sulfhydryl groups in pro-tein. Copper ions increase the oxidation of adrenaline to adrenochrome.
Recently Dhalla, Ganguilly, Rupp, Beamish and Dhalla (1989), measured adrenol u tin in plasma. They found surpris-ingly high concentrations. In rats, injection of adrenaline was followed by a several-fold increase in adrenolutin formation in plasma. The level came down at 15 minutes and in-creased thereafter. Large amounts of in-jected adrenaline released endogenous catecholamines. Injections of adrenochrome and adrenolutin yielded maximum blood levels at 15 minutes. Injections of noradrena-line and dopamine also increased adreno-lutin levels. The natural levels in blood were many times greater than concentrations of adrenaline.
Doubt about the ability of the body to make adrenochrome and its derivatives has been replaced by interest. This is especially true in three areas: (1) neurology (Graham, 1978, 1979; Graham, Tiffany, Bell and Gutknecht, 1978); (2) cardiology (Beamish, Dhillon, Sinsal and Dhalla, 1981; Karmazym, Beamish, Fliesel and Dhalla, 1981; Sinsal, Yates, Beamish and Dhalla, 1981): and more recently, (3) psychiatry (Jeste, Lohr and Mani, 1985; Cadet and Lohr, 1987).
The research in cardiology shows that adrenalin is very readily oxidized into adreno-chrome. Adrenochrome is toxic to myocar-dial tissue and may be responsible for fibril-lation and sudden death under stress. Myo-cardial tissue is very high in the enzyme which oxidizes adrenalin to adrenochrome.
Cocaine blocks two of the enzyme sys-tems the body normally uses to destroy adrenalin, thus forcing more of it into the adrenochrome pathway. Is this the expla-nation for sudden death associated with co-caine abuse?
The neurological studies suggest that dopachrome, the oxidized derivative of L-dopa, is responsible for some of (lie degen-erative changes in the brain. Jeste et al (1985) point out that the cerebral cortical areas rich in catecholamines are prone to age related neuronal loss. Brain stem areas containing high concentrations of dopamine and noradrenalin exhibit signifi-cant neuron loss with aging. These patients also risk developing psychotic symptoms since dopachrome is like adrenochrome
Vitamin B3, niacin or niacinamide, protects brain tissue against some of the toxic effects of adrenochrome such as EEG changes and schizophrenic-like symptoms (Szatmari, Hoffer and Schneider, 1955). In our opinion all patients with Parkinson-ism should be taking vitamin B3. It will not protect them from the ataxia and tremor, but will prevent psychiatric changes (or re-verse them if they have already occurred), and may prevent further loss of neurons,
Are the Aminochromes Hallucinogens?
The two classic hallucinogens are mescalin, derived from the cactus, peyote, and d-lysergic acid diethylamide (d LSD-25) which is extracted from ergot. LSD is the most active of the hallucinogens, i.e, 100-200 mcg will cause a reaction lasting six or more hours. Much more mescalin is required to produce a similar reaction. These compounds do not cause schizo-phrenia, but do cause a reaction in normal people which mimics schizophrenia. They produce what is usually written as “model psychosis.”
Only three of the aminochromes have been tested for hallucinogenic properties: adrenochrome, adrenolutin and leuko-adrenochrome (5.6 dihydroxy N Methyl in-dole). The first two are hallucinogens but the third is not. On the contrary, it is a very effective anti-anxiety compound when given sublingually for some very tense in-dividuals, producing an effect within five to ten minutes. The evidence for these con-clusions is available in The Hallucinogens (Hoffer, Osmond, 1967; Hoffer, 1962). The reactions induced by adrenochrome and by adrenolutin are somewhat different. Adrenolutin causes changes which are more subtle, with fewer perceptual illusions. It tends to flatten mood more and its effect lasts longer. Adrenochrome causes more perceptual changes but they are rarely as pronounced as those caused by LSD or mescalin. Its effect may last a long time. It produced a two-week paranoid depression in one of us (A.H.) and a one-week paranoid depressive reaction with visual illusions in a distinguished colleague of ours.
Adrenochrome potentiated the activity of LSD in a few alcoholics. Between 1954 and 1962 we treated several thousand alcoholics with psychedelic therapy using LSD, usually 200 to 400 mcg. In the usual reaction the first changes would occur in about one hour. Increased anxiety was usually the first reaction. Within two hours they would ex-perience the usual reaction. Anxiety would fluctuate but was seldom high or a prob-lem. However, many alcoholics did not have the usual reaction even with 400 mcg. They remained very tense and uncomfortable all the time. This group did not profit from their experience. In a few patients an in-jection of adrenochrome after two hours would, within a few minutes, bring on the typical LSD reaction. We concluded that LSD did not act as an hallucinogen per se but that it induced an increase in the pro-duction of adrenochrome which was the hallucinogen. An individual who could not make enough adrenochrome would not be able to have the typical LSD reaction. This conclusion was supported by our earlier finding that vitamin B3 markedly reduced the intensity of LSD reactions whether given before or during the LSD reaction. By blocking the adrenochrome effect it would also block the effect of LSD. It would also explain why Brom LSD, a very potent antiserotonin, would not be an hallucino-gen. Brom LSD probably has no effect on adrenalin oxidation and would not increase the formation of adrenochrome. These are interesting speculations. Perhaps now with increasing interest in free radical hypoth-eses and in oxidized derivatives of the catecholamines, scientists will direct their interest back into these areas.
Will Blocking the Production of Amino-chromes be Therapeutic for Schizophrenia?
Our two basic equations immediately directed our attention in 1952 to the need for compounds which would decrease the formation of adrenochrome. We needed compounds that were safe, could be taken over a lifetime and which had no side ef-fects. We realized that any treatment for schizophrenia must be life long. It is im-possible to give ECT or insulin for life, which explains why these treatments were successful for short periods. We wanted to decrease the formation of adrenalin, not stop it, by pulling methyl groups away from noradrenalin. We also knew that adreno-chrome was a respiratory enzyme inhibi-tor and that the respiratory enzymes were made in the body from thiamin, riboflavin and vitamin B3. Increasing the amount of respiratory enzyme is one way of overcom-ing an inhibition. Only one compound, vi-tamin B3, met all these requirements. It is a vitamin (more accurately, an amino acid), water soluble, safe (an LD 50 of 5 grams per kilogram in animals), has few side effects and fewer dangerous side effects, and is a methyl acceptor. Furthermore. it was then known to be the antipellagra vitamin, i.e. a vitamin B3 deficiency caused pellagra. The most prominent effect of pellagra is the schizophrenic syndrome which in its early stages is not distinguishable from schizo-phrenia. We decided to test vitamin B3.
We also wanted to decrease the oxida-tion of adrenalin to adrenochrome, and for this we needed a reducing substance which met the same criteria for safety. The only compound which fit these criteria was ascorbic acid. Thus our first pilot trials were done using a combination of vitamin B3 and ascorbic acid. We also planned on study-ing thiamin and riboflavin but were not able to do so. By this time we were plan-ning our double blind controlled experi-ments. In a double blind experiment, test-ing one compound against placebo is diffi-cult. To add two more compounds would make it impossible. We had no resources, few research personnel and very little money. When our double blind design forced us to select one compound only, it was obvious it would have to be vitamin B3. However, it also forced us not to use ascorbic acid
The first patient treated with large dose of vitamins was Mr. K.C., a catatonic young man who had not responded to in-sulin coma or ECT and was dying. He was given both vitamin B3 and ascorbic acid and was well in thirty days. We believe our re-sults have always been better when both vitamins were used, but we can not point to any controlled experiment to prove this. We routinely now use both,
By 1952 when we needed 500 mg tab-lets, none were available. The largest tab-lets available were 100 mg and contained mostly filler in order to make a decent sized pill. Giving three grams per day, or thirty of these pills, would make most people ill from the filler. In fact, nearly twenty years later, a mental hospital in southern California wanted to repeat our work, but their phar-macy would only supply them with 100 mg tablets, Most of their patients developed nausea and vomiting and the study was destroyed. I believe they blamed the niacin. We therefore obtained a barrelful of pure vitamin B3 crystals, niacin and niacinamide, and these were placed into capsules. A few years later drug companies prepared 500 mg tablets for us. Kirkman Laboratories in Port-land, Oregon, was the first company to pre-pare 500 mg tablets in the USA.
We will not again review the many clinical studies, double blind and open, which prove that schizophrenic patients treated with vitamin B3 have a much bet-ter prognosis. We reported the first double blind controlled experiments in psychiatry cloney Hoffer, Lucy, Osmond, Smythies and Stepamuch (1954). Before tranquilizers were introduced it was the only effective treatment. Tranquilizers rapidly control symptoms but patients on tranquilizers will not recover if this is the only treatment. Tranquilizers replace one psychosis by an-other. However, they are essential for many patients if we are to keep patients out of mental hospitals. The evidence that vita-min B3 is effective is available in a very large orthomolecular literature. From our early studies (four double blind) we concluded:
Modern orthomolecular therapy is more sophisticated, wide-ranging and ef-fective. Treatment includes an optimum combination of nutrition, vitamins in op-timum doses, drugs and psychotherapy. The prognosis for chronic patients is much better today. Our work established one vi-tamin B3, as a useful adjunct to treatment.
This opened up the field, which now in-volves a large number of nutrients. When tranquilizers are used they are decreased gradually as patients respond to the nutri-tional treatment. A combination of drugs and vitamins takes advantage of the rapid-ity of action of the tranquilizers and the efficiency of the orthomolecular treatment in bringing about recovery.
Tranquilizers alone can produce re-markable improvement, but very few pa-tients remain better when they are discon-tinued, and no patient can be normal while on tranquilizers. Airline companies under-stand this and will not permit their pilots to fly if they know they are taking tranquilizers. It is not difficult to under-stand why, one need only accept two propo-sitions as true:
Schizophrenics are prepared to put up with the tranquilizer syndrome, especially when they still remember the previous schizophrenic state. However, later on they are not, for they realize they can not func-tion normally on tranquilizers unless the dose is very small, or unless their job or station in life requires very little; it is not difficult to sit and stare at a blaring TV, even when heavily tranquilized.
We have challenged many to show our error in the two basic statements. No one has. If, then, they are true, it follows that tranquilizers can never make a person nor-mal, for as they begin to approach normal-ity, i.e. lose perceptual symptoms, lose para-noid ideas, and become less depressed, they will respond to the tranquilizer as will any normal person, i.e. they will become sick with the tranquilizer syndrome. Orthomo-lecular treatment works on sick people to get them well, but once they are well serves only to maintain that wellness. Vitamins do not make normal people ill. We doubt any airline company would ground their pilots who are taking vitamins.
Why the Adrenochrome Hypothesis has Been Neglected
The adrenochrome hypothesis has so far withstood the assault of critics and of research data on the three basic counts. These are:
1.Adrenochrome is formed in the body, but we do not know whether more is formed in schizophrenics or where it is made, or are schizophrenics more suscep-tible to the effects of the aminochromes because they lack antioxidants or other protective factors. Future research will set-tle these issues. We need to know where the transformation occurs, in what quan-tities, and why. We need to know the endproducts of catecholamine oxidation and their pathways. We need to know which enzymes are involved and/or dam-aged, and we need more effective blocking agents which are effective in smaller doses but have the safety, and efficacy of vitamins.
That the adrenochrome hypothesis is not destroyed does not prove it is correct. Time will tell. It does prove it is a good, testable hypothesis and will continue to direct research in future as it has in the past. Why, then, has it been ignored for nearly thirty years?
We may be too close to the subject to really understand the reasons why the adrenochrome hypothesis has been ignored for so long. It did receive a certain amount of notoriety at the beginning, but it was quickly shot down by American psychia-trists led by the National Institute of Men-tal Health. A medical historian may one day be able to examine the issues more capa-bly. In our opinion, there were two main classes of opinion: scientific, and political. The political opposition prevented any se-rious examination of the consequences of the adrenochrome hypothesis. Inadequate as it then was, it was able to direct our re-search in Saskatchewan for 15 years, and could have been examined much more quickly and thoroughly by research insti-tutes which grew very quickly in the U.S.A., beginning in 1955.
A. The Climate of Opinion
No ideas spring forth from a vacuum. All new ideas must confront the establish-ment of ideas until a new paradigm is es-tablished. But the establishment of ideas maybe so pervasive and powerful it is able to swamp and overwhelm new ideas. The adrenochrome hypothesis of schizophrenia attacked, head-on, several establishments.
1. In 1954, psychiatrists and psycholo-gists believed that if there was a disease called schizophrenia, and many doubted this, it was due to stresses generated by in-trapsychic or interpersonal relationships. The psychoanalysts had just won the field, routing all the so-called organic psychia-trists. To be labelled organic was as de-meaning as being called a quack. The few biological psychiatrists who survived the onslaught carried on very quietly, with an occasional show of life. Schizophrenic pa-tients were sick because of what had hap-pened to them, or what they thought had happened to them, or they fantasized this pressure from their parents (usually Mom). Kinder analysts did not condemn Mom, while still blaming her, for she had done so unwittingly because of unconscious prob-lems of her own.
The first major assault on these psychosocial hypotheses came with the intro-duction of the model psychosis. The fact that tiny amounts of LSD could produce a major psychosis suggested similar small quantities of an endogenous hallucinogen could be formed. Psychiatrists who were active in research and the academic field between 1951 and 1957 will remember the vigorous controversy this idea generated. The model psychosis idea suggested that schizophrenia was a biological disease. This was intolerable to most academics who had worked so hard to establish that it was a psychosocial phenomenon.
By itself the model psychosis idea would not have gone far, but it was soon reinforced by the tranquilizers. They swept into Canada and then the U.S.A. from France, where they arose from the finding made by Dr. H. Laborit, a surgeon, that antihistamines, discovered in Italy, had marked relaxing and calming effects on people. The tranquilizers were astonish-ingly effective. When one has experienced what psychiatric wards were like in 1955, it is impossible to forget the excitement generated by these powerful drugs. The enthusiasm was boundless and soon led to a massive release of patients from mental hospitals. The drug companies holding the patents soon found themselves in the unique position of having a drug which needed hardly any advertising in mental hospitals. However, they were very gener-ous in their advertising, which helped over-come the resistance from the academics who were still convinced of their psycho-social theories. The rapid establishment of the tranquilizers as the only treatment for schizophrenia was more persuasive than any other event in turning psychiatric at-tention to biological psychiatry.
However, tranquilizer theorists could point to no hypothesis which could account for their activity until much later when the dopamine hypothesis came along. Nor did the fact that tranquilizers were so helpful deter the psychosocial theorists, for it was merely another, even if more effective, seda-tive. The drug companies, ever aware of the sensitivities of psychiatrists, declaimed in their beautiful ads that tranquilizers merely facilitated psychotherapy. Thus, tranquilizers promoted the idea schizophrenia was biologi-cal but did not exclude psychosocial ideas of the cause.
The adrenochrome hypothesis violated the psychosocial hypothesis, for vitamin B3 was not a sedative, nor was it a tranquilizer. How could anyone, ill because he had been exposed to a schizoprenogenic mother, re-cover by taking a vitamin? If they believed he had recovered, what did that do to their favourite hypothesis? It was easier to be-lieve he had not recovered. This was made easier by avoiding the use of vitamins. To this day very few academics have tried the orthomolecular approach. There is the enormous risk one might have to change one’s mind. They believed that orthomolecu-lar treatment was inextricably bound to the adrenochrome hypothesis; that if they ac-cepted one, they would have to accept the other. This of course was nonsense. We used the adrenochrome hypothesis to lead us to vitamins, but we might have come upon it serendipitously. The adrenochrome hypoth-esis may he completely wrong, but this has no hearing on whether vitamin B3 is thera-peutic for schizophrenics.
2. The use of vitamins in very large doses attacked all the classical nutrition-ists who were disciples of the vitamin hy-pothesis, i.e. that vitamins were needed in very small doses. Yet we were using doses of vitamin B3 1000 times the RDA, and doses of ascorbic acid 60 times the RDA. It is believed by these fossilized vitamin theo-rists that larger doses are not needed, are not effective for anything and may be toxic. So convinced are they, that they think it is honourable to invent toxicities when none are present. These theorists have received massive support from the FDA, from ma-jor food industries and from physicians who know almost nothing about nutrition or nutritional supplements. The classical theorists are not easily persuaded. Even though vitamin B3, the niacin form, lowers cholesterol, elevates high density lipopro-tein cholesterol, reduces mortality from cancer and cardiovascular disease, and in-creases longevity, it does not violate their idea, even with 3–6 grams per day (1000 to 2000 times RDA), for they either do not know niacin is a vitamin, or consider it is no longer acting as a vitamin. Most physi-cians think of niacin as a drug, and they have no objections to using drugs in mega-doses, only to vitamins. Niacin’s role in low-ering cholesterol also arose from our Sas-katchewan research into schizophrenia, as a side discovery following the adreno-chrome hypothesis. Today niacin is excit-ing many academics because it has been shown to be so effective in the cardiovas-cular area, will “cure” a large proportion of juvenile diabetics if given within six months of onset, and has many other valuable therapeutic properties.
The medical establishment has a his-tory of about 150 years of denying the im-portant role of malnutrition in causing dis-ease, and in the role of good nutrition in restoring health. This in spite of the fact that the major advances in our understanding of nutrition have been made by physicians who had to fight their colleagues for years before their ideas became acceptable: Francois Magendie (whole wheat bread supported life, white bread did not), James Lind (citrus fruits prevent scurvy), R. Chittenden (veg-etarianism), J. Goldberger (pellagra, a disease caused by poor diets), A. McCann (disease arose from inadequate diets), Harvey Wiley (tried to keep our food clean), Elmer McCollum (vitamins A and B), Max Bircher-Benner (importance of whole foods, especially vegetables), R. McCarrison (importance of whole foods), H. Bieler (im-portance of good food), John Boyd (on good food and health), Max Gerson (treatment of cancer), Seale Harris (hypoglycemia), and
T. L. Cleave (the saccharine disease). I have not listed an equally impressive group still working and trying to teach their col-leagues. The amazing controversies in which they were engaged is detailed in Barbara Griggs’ excellent book The Food Factor. By tradition, medical schools do not teach clinical nutrition, and their graduates seldom overcome this major defect in their education.
Another problem orthomolecular therapists faced was the over-valuation and extreme popularity of the tranquilizers. This was so intense psychiatrists refused to recognize tardive dyskinesia for many years after it had been described, for how could something so undesirable accompany the very helpful tranquilizers? Not only could vitamins not compete for attention with tranquilizer (xenobiotic) physicians, there was no need to be interested since tranquilizers had provided the answer. Another aspect was the rapidity of action of the drugs. Psychoanalysis had taught psychiatrists to be patient. Drugs taught them to be impatient, to demand rapid responses. Vitamin therapists need less patience than analysts, but more than drug therapists, for orthomolecular therapy works slowly, but it keeps on working whereas drugs alone eventually work against recovery. Psychiatrists accustomed to a rapid response to drugs in days or weeks would not wait months for ortho-molecular treatment to achieve its maxi-mum response.
B. Sloppy Science
By this we refer to sloppy scholarship,
i.e. failure to read the literature and record accurately what was found. Again, the APA report contains a host of beautiful exam-ples. These are pointed out in our Reply (Hoffer and Osmond, 1976).
We know of many examples of sloppy or bad science which were used to attack the adrenochrome hypothesis. One of the best examples was Dr. Max Rinkel’s use of adrenochrome semicarbazide to test adrenochrome’s hallucinogenic properties. Not a chemist, he was footed by a drug company which had been marketing the semicarbazide for staunching blood flow. It was used by many surgeons and known as stable adrenochrome. It was not adreno-chrome. Dr. Rinkel later published a cor-rection but his first report, presented at an American Psychiatric Association meeting, received wide publicity and is still quoted by American textbooks of psychiatry writ-ten by eminent psychiatrists. Dr. Rinkel’s correction was read at an obscure meeting at the Allan Memorial Hospital in Montreal and has been ignored by almost everyone since, even though we drew it to their at-tention. They were not pleased when we informed them and continued to refer only to the first Rinkel report.
Other examples include a brief study on chronic, deteriorated schizophrenics who were given one gram of niacin per day for twelve days, and based upon their lack of response it was concluded vitamin B3 had no merit. The APA Task Force Report on Megavitamin Therapy abounds with such examples, which was treated with the utmost respect.
C. Other Difficulties
We will list merely two of these:
The politics of science is not much different from politics in general; it is a conflict of ideas. The only difference is that most people unfamiliar with science are surprised when they discover science is quite like politics. They had thought scien-tists were above the thrust and parry of politics. Scientific politics have held back innovation in science for at least 300 years and perhaps longer. The politics of the adrenochrome hypothesis is a specific ex-ample of a much greater problem in sci-ence. The problem is how do new ideas become established, and how can one be sure these are good ideas (like the use of tranquilizers) and not bad ideas (like the psychoanalytic hypothesis)? We can not depend upon one person to make this judgement, for establishment leaders did not become leaders because they were bold and innovative and attacked the establishmerit. Dr. Linus Pauling asked Dr. Karl Landsteiner how he had developed his research ideas. He replied, “I think of thou-sands of ideas and throw away the bad ones.” Unfortunately, the Paulings and Landsteiners are very rare and seldom in-fluence the medical establishment.
In medicine about forty or more years are required in most cases before new ideas become part of the establishment. Some-times it takes less time. It appears likely the use of niacin to lower cholesterol, and de-crease deaths, may come in just under the wire - forty years. We first reported it in 1955. Only within the past two years has it become known to the academic establish-ment. It is well on the way, even though most physicians in the field still have not heard of it.
We hope a discussion of the politics of the adrenochrome hypothesis will alert the leaders of the medical establishment of the problem. At once we want to make it clear there was no paranoid conspiracy involved. There was no single person or single estab-lishment orchestrating the opposition to the adrenochrome hypothesis. What might appear to be a conspiracy was rather a spir-ited defence by the establishment as if it had a leader. They were impelled by the need to maintain the establishment. They have attacked other investigators as well, as have establishments elsewhere. But two institutions, the National Institute of Men-tal Health and the American Psychiatric Association, have taken a leading role, and a few of their members like S. Kety, L. Mosher and M. Lipton have been most ac-tive. The first two were very influential within the NIMH and the last chaired the APA committee for the APA report. Fortu-nately, Dr. Linus Pauling entered the field in 1966, especially after he published his paper “Orthomolecular Psychiatry” in Sci-ence, 1968.
The National Institute of Mental Health was created because the American government realized that too little was known about mental illness and how to deal with it most successfully. We can not remember when the huge building was dedicated, but one of us (A.H.) stood on the site on the edge of Washington, D.C., when it was still a tiny builders’ shack. The psy-chiatrist in charge described some of his hopes about NIMH to A.H. Most of his hopes have not been achieved.
The first administrators of NIMH were psychoanalysts. This is not surprising since analysis had captured most of the academic centres, beginning with the Ivy League universities. Dr. John Weir, Medical Direc-tor, Rockefeller Foundation, in 1954 told us that the Foundation funds used to start up these psychiatric departments had been wasted. Apparently the Rockefeller Foun-dation did not pass on their conclusion to the new NIMH. The need to be psychoana-lytically oriented was so powerful, Dr. S. Kety, trained in physiology, became an ana-lysand for two years. NIMH was not very sympathetic to any biochemical or biologi-cal view of schizophrenia. Many years later their Schizophrenia Section, directed by Dr.
L. Mosher, preferred psychosocial investi-gations to biological ones. He was a dedi-cated follower of the English poet-psychia-trist Dr. R. D. Laing. In his view he could not accept that vitamins could help schizo-phrenics even if every American psychia-trist did believe so. This was a statement he made at one of our hostile meetings between a few NIMH leaders and a few or-thomolecular psychiatrists. In his view, a schizophrenic who improved after a year of milieu therapy was better off than if he or she had made the same degree of im-provement after a few weeks on tran-quilizers. He would, of course, never use orthomolecular techniques. NIMH tried to protect the analytic orientation by resist-ing funding tranquilizer research. It re-quired a coalition of senators and congress-men who demanded they liberalize their policy before they did so. The top adminis-trators were moved on to less demanding jobs, and major research grants were awarded to a large number of research groups. It appears that one or two studies, both positive, are not believed, and one required hundreds and thousands of stud-ies all showing the same thing.
After that there was a slow drift of in-terest in biological psychiatry. An exami-nation of recent reports from NIMH indi-cates they have gone a long way. This may be the atmosphere which allowed the re-cent reports to appear. Cadet, Lohr and Jeste (1986), Cadet and Lohr (1987), Jeste, Lohr and Mani (1985), and Cadet and Lohr (1987) discussed the hypothesis that oxi-dized derivatives of some catecholamines are involved in the etiology of schizophre-nia. They had concluded that the dopamine hypothesis was inadequate for a number of reasons, but that free radicals or oxidized derivatives following increased dopamine turnover might be involved and could ac-count for many of the clinical findings of the schizophrenics, especially its progres-sion in chronic schizophrenia to produce the defect state. However, they did not re-fer to a single adrenochrome paper or even to the word adrenochrome, although they came close when they wrote about free radicals formed during enzymatic and nonenzymatic metabolism of catechol-amines. It is possible they considered auto-oxidized compounds from dopamine and noradrenalin not to be indoles or aminochromes (Hoffer, 1999).
Thirty years ago, it was no secret to
U.S.A research groups that NIMH was ac-tively disinterested in pursuing adreno-chrome research. In one case, a director of research was advised no grant would be made to his group if he persisted in study-ing adrenochrome. In another example a study of vitamin B3 as treatment for schizo-phrenia was not given to a psychiatrist in the midwest because he had recommended one of us (A.H.) be a consultant to his study. It was instead allocated to a group in New Jersey which did not have the same precon-dition. Dr. L. Mosher was also on the APA committee which supported Dr. M. Lipton’s previous conclusion that there was no merit in orthomolecular psychiatry. He had come to this conclusion even before the committee had been created by the APA.
The American Psychiatric Association
The APA reflects the views of the ma-jority of its members. When the pressure on American psychiatry was great enough, APA responded by creating a committee, the APA Task Force on Megavitamins and Orthomolecular Therapy, chaired by Prof.
M. Upton. The APA must have known Dr. Lipton had already publicly declared him-self a vigorous opponent of megavitamin therapy. They allowed him to hand-pick his committee, which consisted of: (1) one of his junior professors in his department of psychiatry; (2) Dr. L. Mosher, (3) Dr. T. Ban, and two others. With these three commit-tee persons and their well-publicized views against megavitamin therapy, it is not sur-prising the final report was very critical, hostile and negative. We have replied to this report (Hoffer and Osmond, 1976), and will not examine it any further.
Since then, the satellite organizations of the APA and psychiatric establishments at universities and at state government lev-els have used this APA report to deflect criti-cism from patients and their families. We doubt they have read the APA report care-fully, or researched how it dealt with the references. Certainly they did not read our Reply. The Canadian Psychiatric Association based their negative report on the APA re-port, believing big brother must be right.
In 1968 and 1974, Dr. Linus Pauling examined the relation of vitamins to psy-chiatry. From his earliest studies of the chemical basis of sickle cell anemia, he had been interested in the molecular basis of medicine. By 1968 Dr. Pauling was con-vinced that using large doses of vitamins was biochemically sound and that their use in treating some mental diseases was jus-tified. His paper in Science marked his en-try as a new player on the scene. The power of his scientific accomplishments and the prestige of his name alerted the scientific world. There were two reactions. Biochem-ists were more interested, as were a few doctors. Slowly, more research reports deal-ing with vitamins were published in medi-cal journals. But most doctors dismissed his ideas. They began to spread a rumour that Linus was becoming senile, or how could a Ph.D., non-M.D. scientist take a public stance on a subject they deemed entirely medical (psychiatric). Orthomo-lecular psychiatry is sophisticated, etiological and more effective than stand-ard medicine which depends only on drugs (Hoffer, 1989).
The aminochromes undoubtedly are involved in almost every reaction in which catecholamines play a part. A vast new area has now opened for physiological and bio-chemical research. Thus, Ganguly (1989) and Ganguly, Beamish and Dhalla (1989) state “...oxidation products of catechol-amines, such as adrenochrome, rather than catecholamines per se, may be involved in catecholamine-induced myocardial cell damage. Previous studies have revealed that adrenochrome is capable of inducing coro-nary spasm, arrhythmias, ultrastructural changes and ventricular dysfunction.” They suggest damage caused by pheochromocyto-mas is due to adrenochrome. Extra adrena-line is oxidized when other mechanisms for inactivating catecholamines are saturated.
Catecholamines are involved in stress reactions and are neurotransmitters. Any compound (drug) which potentiates or inhib-its the reactivity of catecholamines will be modulated by the presence of the correspond-ing aminochromes. The action of all the tranquilizers, antidepressants, and other psychoactive drugs will have to be reevaluated. It is likely subjects low in aminochromes will respond differently than subjects with high blood levels.
Aminochromes will surely have very important functions. They are not only by-products of catecholamine oxidation. It is necessary to reexamine Dr. F. E. Barr’s very important work, “Melanin: The Organizing Molecule” (1983). In his abstract Barr wrote:
“The hypothesis is advanced that (neuro)-melanin (in conjunction with other pigment molecules such as the isopen-tenoids) functions as the major organiza-tional molecule in living systems. Melanin is depicted as an organizational “trigger” capable of using established properties such as photon-(electron)-photon conver-sions, free radical-redox mechanisms, ion exchange mechanisms, and semicon-ductive switching capabilities to direct energy to strategic molecular systems and sensitive hierarchies of protein enzyme cascades. Melanin is held capable of regu-lating a wide range of molecular interac-tions and metabolic processes primarily through its effective control of diverse cova-lent modifications.”
The main question remains. Is the schizophrenic syndrome caused by an oxi-dation-reduction state which: (1) favours excess formation of aminochromes; (2) in-hibits the elimination of these amino-chromes. The evidence which favours this hypothesis is stronger than ever. Only re-search, exemplified by cardiovascular re-search scientists, will provide the evidence we need. Will psychiatry once more lag several decades behind in examining these issues?
Barr FE, Saloma JS and Buchele MJ: Melanin; the organizing molecule. Medical Hypothesis, 11:1140,1983
Beamish RE. Dhillon KS, Sinsal PK and Dhalla NS: Protective effect of sulfinpyrazone against cat-echolamine metabolite adrenochrome-induced arrhythmias. Am. Heart J., 102:149-152,1981.
Cadet JL and Lohr JB: Free radicals and the devel-opmental pathobiology of schizophrenic burn-out. Integrative Psychiatry, 5:40-48, 1987.
Cadet JL, Lohr JB and Jeste DV: Free radicals and tardive dyskinesia. Trends Neurosci. TINS, 9:107-108, 1986.
Clancy J, Hoffer A, Lucy J, Osmond H, Smythies J and Stefaniuk B: Design and planning in psy-chiatric research as illustrated by the Weyburn Clinic Nucleotide Project. Bull. Menn. Clinic, 18:147-153, 1954.
Dhalla KS, Ganguly PK, Rupp H, Beamish RE and Dhalla NS: Measurement of adrenolutin as an oxidation product of catecholamines in plasma. Molecular and Cellular Biochem., 87:85-92, 1989.
Ganguly PK: catecholamines and cardio vascular disorders: pathophysiologic considerations. Am. Heart J., 118: 868-872,1989.
Ganguly PK, Beamish RE and Dhalla NS: Catecho-lamine cardiotoxicity in pheochromocytoma. Am. Heart J., 6:1399-1400,1989.
Ganguly PK, Lee S, Beamish RE and Dhalla NS: Altered sympathetic system and adreno-receptors during the development of cardiac hypertrophy. Am. Heart J., 118:520-525, 1989.
Graham DG: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic Quinones. Molecular Pharmacol-ogy, 14:633-643, 1978.
Graham DG: On the origin and significance of neuromelanin. Arch. Path. and Lab. Med., 103:359-362,1979.
Graham DR: Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neu-rotoxicity and Parkinson’s disease. Neurotox-icity, 5:83-95, 1984.
Graham DG, Tiffany SM, Bell WR and Gutknecht WF: Autooxidation versus covalent binding of Quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C1300 neuroblastoma cells in vitro. Molecular Pharmacology, 14:644653,1978.
Heacock RA: The chemistry of adrenochrome and related compounds. Chem. Reviews, 59:181237,1959.
Heacock RA: The aminochromes. Advances in Heterocyclic Chem., 5:205-290, 1965.
Hegedus ZL and Altschule MD: Aminochromes III. Transformation of epinephrine, adrenochrome and adrenolutin into plasmasoluble melanins during incubation in human blood plasma. Arch. Biochem. Biophys., 126:388-392, 1968.
Hegedus ZL and Altschule MD: Aminochromes IV. Hemolysis associated with the transformation of epinephrine, adrenochrome and adrenolutin into rheomelanins in human whole blood. Arch. Ing. Pharmacodyn. Ther., 186:39-47, 1970.
Hegedus ZL and Altschule MD: Aminochromes V. Excessive hemolysis associated with the forma-tion of rheomelanins during incubation of adrenochrome and adrenolutin in the bloods of chronic schizophrenic patients. Arch. Ing. Pharmacodyn. Ther., 186:48-53, 1970
Hegedus ZL, Kuttab SH, Altschule MD and Nayak
U: Isolation of melanin from human plasma lipofuscin. Arch. Internationales de Physiologie et de Biochemie, 89:393-398, 1981.
Hoffer A: The effect of adrenochrome and adrenolutin on the behavior of animals and the psychology of man. Ing. Rev. Neurobiol., 4:307371, 1962
Hoffer A: The adrenochrome hypothesis of schizo-phrenia revisited. J. Ortho. Psych., 10:98-118, 1981.
Hoffer A: Oxidation reduction and the brain. J. Ortho. Psych., 12:292-301, 1983.
Hoffer A: Dopamine, noradrenalin and adrenalin metabolism to methylated or chrome indole derivatives: two pathways or one? J. Ortho. Psych., 14:262-272, 1985.
Hoffer A: Letter to the editor. Integr. Psych. 6:243 only, 1988.
Hoffer A: Orthomolecular Medicine for Physicians. Keats Publishing, Inc., New Canaan, CT, 1989.
Hoffer A and Kenyon M: Conversion of adrenaline to adrenolutin in human blood serum. AMA Archives Neur. and Psychiatry, 77:437-438, 1957.
Hoffer A and Osmond H: The Hallucinogens. Aca-demic Press, New York, 1967.
Hoffer A and Osmond H: In Reply to the American Psychiatric Association Task Force Report on Megavitamins and Orthomolecular Therapy in Psychiatry. Canadian Schizophrenia Foundation, 1976.
Hoffer A, Osmond H and Smythies J: Schizophre-nia: a new approach. II. Results of a year’s re-search. J. Ment. Set., 100:29,1954.
Jeste DV, Lohr JB and Mani R: Quantitative neu-ropathology and aging. In, Biological Psychia-try 1985, IV World Congress, Sept. 8-13, Phila-delphia. Ed. Shagass, C. et al.
Karmazym M, Beamish RE, Fliesel L and Dhalla NS: Adrenochrome induced coronary artery constriction in the rat heart. J. Pharmacol. Exp. Ther., 219:225-230, 1981.
Leach BE and Heath RG: The in vitro oxidation of epinephrine in plasma. AMA Arch. of Neural. and Psychiatry, 76:444450, 1956.
Osmond 14 and Smythies J: Schizophrenia: a new approach, J. Ment. Sci., 98:309-315, 1952.
Pauling L: Orthomolecular psychiatry. Science, 160:265-271, 1968.
Pauling L: On the orthomolecular environment of the mind; orthomolecular theory. Am. J. Psy-chiatry, 131:12511257,1974.
Sinsal PK, Yates JC, Beamish RE and Dhalla NS: In-fluence of reducing agents on adrenochrome induced changes in the heart. Arch. Pathol. Lab. Med., 105:664-669,1981.
Szatmari A, Hoffer A and Schneider R: The effect of adrenochrome and niacin an the electroen-cephalogram of epileptics. Am. J. Psychiatry, 3:603-616,1955.
This website is managed by The Center For The Improvement Of Human Functioning International
Information on Orthomolecular.org is provided for educational purposes only. It is not intended as medical advice.
A Non-profit Medical, Research and Educational Organization
3100 North Hillside Avenue, Wichita, KS 67219 USA
Phone: 316-682-3100; Fax: 316-682-5054
© (CIHFI) 2004 - 2007
Consult your orthomolecular health care professional for individual guidance on specific health problems.
Information on Orthomolecular.org is provided for educational purposes only. It is not intended as medical advice.